New drug combo as first treatment for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign the consent form.
- You have advanced or stage IV non-small cell lung cancer (NSCLC) that cannot be removed with surgery or treated with radiation.
- Your PD-L1 test result is 1% or higher.
- You have not received chemotherapy, targeted therapy, or immunotherapy for your lung cancer before.
- Your cancer does not have certain gene changes (EGFR, ALK, ROS1) that are common in adenocarcinoma.
- You are generally healthy enough to be up and about (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (nab-paclitaxel, lenvatinib, and pembrolizumab) for people with advanced non-small cell lung cancer whose cancer grew after first-line treatment with immunotherapy and chemo. The goal is to see if this combination can help control the cancer.
This trial tests a new combination for advanced lung cancer: an immunotherapy drug (tislelizumab) plus standard chemotherapy, and adds a common allergy medicine (diphenhydramine) to see if it improves outcomes. It's for people who haven't had prior systemic treatment for their lung cancer and are generally healthy.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.